Posted by Michael Wonder on 24 Aug 2021
FDA grants breakthrough device designation for renal failure
23 August 2021 - ImpediMed is pleased to announce SOZO has received FDA breakthrough device designation for a proposed indication in a renal patient population.
ImpediMed intends to use its well established SOZO bioimpedance spectroscopy platform to provide an exact measure of fluid volume to remove during a dialysis session.
